A Long-term Extension Study of JNJ-77242113 in Participants With Moderate-to-Severe Plaque Psoriasis

• Status: Not yet recruiting
• Trial end date: 2023-11-13
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to evaluate long-term clinical response of JNJ-77242113 treatment in participants with moderate-to-severe plaque psoriasis.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Janssen Research & Development, LLC

Criteria

Inclusion Criteria:

• Must have completed the Week 16 visit in Protocol 77242113PSO2001

• In the opinion of the investigator, may benefit from inclusion in this long term extension (LTE) study

• Must agree to avoid prolonged sun exposure and avoid use of tanning booths or other ultraviolet light sources during the study

• Must agree to discontinue all topical therapies that could affect psoriasis or the psoriasis area severity index (PASI) or investigator's global assessment (IGA) evaluation, other than nonmedicated emollient and salicylic acid shampoos, prior to first administration of study intervention

• Agree not to receive a live virus or live bacterial vaccination during the study, or within 4 weeks after the last administration of study intervention

Exclusion Criteria:

• Was permanently discontinued from study intervention in Protocol 77242113PSO2001 for any reason

• Has received any biologic therapy or experimental therapy since completion of the originating study, 77242113PSO2001

• Has received any live virus or bacterial vaccination within 12 weeks before the first administration of study intervention

• Has received the bacille Calmette-Guerin (BCG) vaccine within 12 months of the first administration of study intervention

• Currently has hepatitis B surface antigen (HBsAg) or hepatitis C antibody (anti-HCV) positive, or has other clinically active liver disease, or tests positive for HBsAg or anti-HCV